Elagolix is an oral, nonpeptide GnRH antagonist, and recent studies showed that it is efficient in controlling both nonmenstrual pelvic pain and dysmenorrhea secondary to endometriosis, with an acceptable safety profile at a dosage of 150 mg/day that produces partial estrogen suppression [12-14]. This evidence concerns the gene GNRH1 and endometriosis.